Dr. Kevin Becker

Claim this profile

Maimonides Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
12 drugs studied

Area of expertise

1

Lung Cancer

Kevin Becker has run 4 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage III
Stage I
2

Non-Small Cell Lung Cancer

Kevin Becker has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage I

Affiliated Hospitals

Image of trial facility.

Maimonides Medical Center

Image of trial facility.

Maimonides Cancer Center

Clinical Trials Kevin Becker is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

More about Kevin Becker

Clinical Trial Related

11 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Kevin Becker has experience with

  • Biospecimen Collection
  • Crizotinib
  • Carboplatin
  • Gemcitabine Hydrochloride
  • Paclitaxel
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kevin Becker specialize in?

Is Kevin Becker currently recruiting for clinical trials?

Are there any treatments that Kevin Becker has studied deeply?

What is the best way to schedule an appointment with Kevin Becker?

What is the office address of Kevin Becker?

Is there any support for travel costs?